A Novel Stimulation Protocol and the Conventional Low Dose Step-up and Step Down Regimens

NCT ID: NCT01112111

Last Updated: 2010-04-28

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 225 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2010-05-31

Brief Summary

This study is designed to compare the efficacy of a novel stimulation protocol with the conventional low dose step-up and step down regimens in older than 30 years PCOS patients undergoing in vitro fertilisation. The novel regime was proposed under the basis of the combined effectiveness of the two standard protocols to induce a uniform follicular growth and forms a continuation to the author's previously published results examining a similar approach in younger PCOS candidates. In total 225 patients have been recruited for this study. The stimulation protocol will be assigned under the basis of prospective randomization using sealed and numbered envelopes. All patients will be down regulated using a desensitisation agent administered on day 2 of spontaneous or induced withdrawal bleeding. The initial dosage in the low dose step-up regimen (group A) will be 150 IU/d of FSH for the first 6 days followed by an increase of 75 IU thereafter. In the step-down regimen (group B) patients will administer a starting dose of 300 IU/d of FSH for the first 3 days followed by a decrease to 225 IU/d for the next 3 days. This dosage will be further decreased to 150 IU/d or sustained at 225 IU (according to the initial response) until the day of the hCG injection. Group C, patients received 225 IU on day 1 followed by a decrease to 150 IU on day 2. On day 3 the dosage will be increased back to 225 IU. This alternation of injection dosage will be followed until day 6. According to the initial ovarian response the dosage will be sustained at 225 IU/d or 150 IU/d until the day of the hCG injection. The 10,000 IU hCG will be administered when at least two follicles had reached a mean diameter of 18 mm and the serum E2 levels were consistent with the ultrasound findings. Egg retrieval will be undertaken at 35 hours after the administration of the hCG injection. Oocytes recovered will be inseminated 4 hours post egg collection. Patients will receive 3 embryos on the third day of development. The luteal phase will be supported by progesterone suppositories starting on the day of the egg collection. A positive outcome will be detected by a serum β-hCG analysis 13 days after embryo replacement. The presence of a fetal heart pulse on ultrasound 3 weeks later confirmed a clinical pregnancy.

Conditions

PCOS

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

75 PCOS Patients - step up regime

Group A will be comprised of 75 patients and these will receive a low dose step stimulation regime

mode of gonadotropin administration

Intervention Type: DRUG

Low dose step-up administration Step down administration sequential administration

75 PCOS patients -step down regime

Group B will be comprised of 75 patients who will receive a step down regime of stimulation

mode of gonadotropin administration

Intervention Type: DRUG

Low dose step-up administration Step down administration sequential administration

75 PCOS patients - sequential regime

Group C will be comprised of 75 patients who will be treated using a sequential stimulation regime

mode of gonadotropin administration

Intervention Type: DRUG

Low dose step-up administration Step down administration sequential administration

Interventions

mode of gonadotropin administration

Low dose step-up administration Step down administration sequential administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Failure to ovulate after CC treatment

• Over than 30 years of age No Previous IVF attempts
• Patent Fallopian Tubes
• Normo-spermic partners

Exclusion Criteria

• Secondary Infertility
• Younger than 30 years
• Older than 36 years
• Other infertility cause

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 36 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genesis Center for Fertility & Human Pre-Implantation Genetics

OTHER

Sponsor Role: lead

Responsible Party

Genesis Centre for Fertility and Human Pre-implantation Genetics

Locations

Genesis Centre for Fertility and Human Pre-implantation Genetics

Limassol, Limassol District, Cyprus

Countries

Cyprus

Other Identifiers

PCOS2

Identifier Type: -

Identifier Source: secondary_id

livfe67

Identifier Type: -

Identifier Source: secondary_id

PCOS

Identifier Type: -

Identifier Source: org_study_id